Prakash Achaary

Chris Hurley Asked to Renew Three-Year Term as Americas Director of Leading Data Sciences Organization PhUSE

|
Chris Hurley PhUSE MMS Holdings data sciences real world evidence RWE RWD real world data pharmaceuticals biotech healthcare services consultant vendor CRO

CANTON, Mich. (November 2, 2018) – MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced that one of its leader’s in programming and data sciences, Chris Hurley, has been asked and has accepted a second three-year term as Americas Director of PhUSE – an independent, global organization for more than 8,000 data managers, biostatisticians, clinical programmers, and eClinical IT professionals.

Detroit-Area Life Sciences Firm Pledges More Than $250,000 in Employee Hours to Local Volunteer Initiatives

|
#OneMMS volunteer campaign MMS Holdings Canton Michigan CRO corporate social responsibility clinical research organization contract research organisation cro mms holdings covid-19 coronavirus

CANTON, Mich. (October 5, 2018) – MMS Holdings Inc. (MMS) – award-winning, data-focused CRO – announced today its renewed dedication to the local communities surrounding Detroit and Ann Arbor by allocating a substantial amount of colleague time to volunteer initiatives over the next year. Re-launched as part of its #OneMMS campaign, the value of this investment locally is worth $251,640.

MMS Supported Clinical Data Aspects in Gemphire Therapeutics Meeting its Primary Endpoint in Gemcabene Study

|
Gemphire mms holdings Gemcabene

Canton, Mich. (July 10, 2018) – MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced today its integrated support for Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH). MMS supported data aspects for Gemphire in achieving its primary endpoint…

MMS Promotes Two Leaders at its Asia Headquarters amid Strong Growth Period

|
mms holdings clinical research organization CRO data management vendor services consultant health analytics collective real world data real world evidence julia computing mit university of Maryland Baltimore partner partnership FSP model drug development

Bangalore, India (June 7, 2018) – MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced today two major promotions at its Asia headquarters, including Dr. Arunima Sen has been promoted to the position of Head, Drug Safety and Medical Writing in India, and Nandini Vijaisimha has been promoted to the position of Head, HR and Administration in India.

MMS reaches an employee training milestone of 700 pharma industry courses

|
MMS University

Posted April 13, 2018
MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced today that it has surpassed a training milestone, now with more than 700 training courses available in their learning management system. This platform offers education to all MMS colleagues across North America, Europe, India, and South Africa in a variety of formats from instructor led to self-directed sessions.

MMS Selected by Paratek to Support its NDA Submissions for Omadacycline

|
Paratek Pharmaceuticals

Poster November 15, 2017
MMS Holdings Inc. (MMS) announced today that it was selected by Paratek Pharmaceuticals, Inc., (NASDAQ: PRTK) to support the development of its U.S. new drug applications (NDAs) for omadacycline. Paratek is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Since its selection in June, MMS has been assisting in drafting, assembling and publishing the clinical components of the omadacycline NDAs for the U.S. Food and Drug Administration (FDA) in acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).